Arterial Thrombosis - Pipeline Review, H2 2018 - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Sep 13, 2018--The “Arterial Thrombosis - Pipeline Review, H2 2018” drug pipelines has been added to ResearchAndMarkets.com’s offering.
This pipeline guide provides comprehensive information on the therapeutics under development for Arterial Thrombosis (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Arterial Thrombosis (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Arterial Thrombosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes; the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 6 and 1 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 5 molecules, respectively.
The pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Companies FeaturedAstellas Pharma Inc. Bristol-Myers Squibb Co. MDI Therapeutics Inc. Sanofi Thromboserin Ltd. XBiotech Inc.
Key Topics Covered
2. Report Coverage
3. Arterial Thrombosis - Overview
4. Arterial Thrombosis - Therapeutics Development
5. Pipeline Overview
6. Pipeline by Companies
7. Pipeline by Universities/Institutes
8. Products under Development by Companies
9. Products under Development by Universities/Institutes
10. Arterial Thrombosis - Therapeutics Assessment
11. Assessment by Target
12. Assessment by Mechanism of Action
13. Assessment by Route of Administration
14. Assessment by Molecule Type
15. Arterial Thrombosis - Companies Involved in Therapeutics Development
16. Astellas Pharma Inc.
17. Bristol-Myers Squibb Co.
18. MDI Therapeutics Inc.
20. Thromboserin Ltd.
21. XBiotech Inc.
22. Arterial Thrombosis - Drug Profiles
23. ASP-6537 - Drug Profile
24. BMS-654457 - Drug Profile
25. BMS-884775 - Drug Profile
26. BMS-986120 - Drug Profile
27. Fusion Protein to Antagonize ITGA2B and ITGB3 for Arterial Thrombosis and Ischemic Cerebral Stroke - Drug Profile
28. OA-150 - Drug Profile
29. Peptide to Inhibit PAI-1 for Arterial Thrombosis and Pulmonary Thromboembolism - Drug Profile
30. PZ-128 - Drug Profile
31. S-007867 - Drug Profile
32. SAR-216471 - Drug Profile
33. Small Molecule to Inhibit Integrin alpha 2 beta 1 for Arterial Thrombosis - Drug Profile
34. Small Molecule to Inhibit PAI1 for Immunology, Respiratory and Cardiovascular Disease - Drug Profile
35. Small Molecules to Inhibit Factor XIa for Arterial Thrombosis - Drug Profile
36. THL-001 - Drug Profile
37. Xilonix - Drug Profile
38. Arterial Thrombosis - Dormant Projects
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/2xswb4/arterial?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20180913006038/en/
Laura Wood, Senior Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Cardiovascular Drugs
INDUSTRY KEYWORD: HEALTH CARDIOLOGY PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 09/13/2018 04:00 PM/DISC: 09/13/2018 04:01 PM